A Novel Agent Tasquinimod Demonstrates a Potent Anti-Tumor Activity in Pre-Clinical Models of Multiple Myeloma

被引：3

作者：

Ramachandran, Indu R. ^{[1
]}

Lin, Cindy ^{[1
]}

Chase, Tess ^{[2
]}

Gabrilovich, Dmitry ^{[1
]}

Nefedova, Yulia ^{[1
]}

机构：

[1] Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

来源：

BLOOD | 2014年 / 124卷 / 21期

关键词：

D O I：

10.1182/blood.V124.21.5729.5729

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] The novel, irreversible proteasome inhibitor PR-171 demonstrates potent anti-tumor activity in pre-clinical models of multiple myeloma, and overcomes bortezomib resistance.
Kuhn, Deborah J.
Chen, Qing
Voorhees, Peter M.
Strader, John S.
Shenk, Kevin D.
Sun, Congcong M.
Demo, Susan D.
Bennett, Mark K.
van Leeuwen, Fred W.
Orlowski, Robert Z.
BLOOD, 2006, 108 (11) : 987A - 988A
[2] CD47 ANTIBODY, AO-176 DEMONSTRATES POTENT ANTI-TUMOR ACTIVITY IN PRE-CLINICAL SOLID TUMOR XENOGRAFTS AS A SINGLE AGENT AND IN COMBINATION WITH MULTIPLE CLASSES OF THERAPEUTICS
Andrejeva, Gabriela
Capoccia, Benjamin
Delston, Rachel
Donio, Michael
Hiebsch, Ronald
Puro, Robyn
Wilson, Casey
Kashyap, Arun
Pereira, Daniel
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A282 - A282
[3] Anti-tumor activity of calcitriol: pre-clinical and clinical studies
Trump, DL
Hershberger, PA
Bernardi, RJ
Ahmed, S
Muindi, J
Fakih, M
Yu, WD
Johnson, CS
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2004, 89-90 (1-5): : 519 - 526
[4] The Novel Protein HSF1 Stress Pathway Inhibitor Bisamide CCT361814 Demonstrates Pre-Clinical Anti-Tumor Activity in Myeloma
Menezes, Karen
Aram, Grace
Mirabella, Fabio
Johnson, David C.
Sherborne, Amy L.
Houlston, Richard S.
Cheeseman, Matthew D.
Pasqua, Elisa
Clarke, Paul
Workman, Paul
Jones, Keith
Kaiser, Martin F.
BLOOD, 2017, 130
[5] Discovery of novel potent and selective inhibitors of PRMT5 with anti-tumor activity in hepatocellular carcinoma and lung pre-clinical models
Gonzalvez, Francois
Vandyck, Koen
Debing, Yannick
Gupta, Kusum
Misner, Dinah
Zhang, Qingling
Liu, Jyanwei
Stoycheva, Antitsa
Stevens, Sarah
Symons, Julian
Beigelman, Leonid
Raboisson, Pierre
Deval, Jerome
CANCER RESEARCH, 2020, 80 (16)
[6] Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models
Stefka, Andrew T.
Johnson, David
Rosebeck, Shaun
Park, Jae-Hyun
Nakamura, Yusuke
Jakubowiak, Andrzej J.
CANCER MEDICINE, 2020, 9 (01): : 324 - 334
[7] Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Baker, Amanda F.
Hanke, Neale T.
Sands, Barbara J.
Carbajal, Liliana
Anderl, Janet L.
Garland, Linda L.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2014, 33
[8] Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
Amanda F Baker
Neale T Hanke
Barbara J Sands
Liliana Carbajal
Janet L Anderl
Linda L Garland
Journal of Experimental & Clinical Cancer Research, 33
[9] Anti-tumor efficacy of SMARCA degraders in pre-clinical models of cancer
Satyam, Leena Khare
Sasmal, Sanjita
Pothuganti, Manoj K.
Sreevidya, M. R.
Ettam, Ashokk
Nunna, Sireesha
Roshaiah, Marla
Chithaluru, Shankaraiah
Pallepati, Rangarao
Pawar, Amitkumar A.
Narukulla, Leela P.
Sripathi, Raghunadh A.
Tgore, Suraj
Nankar, Rakesh P.
Charamanna, K. B.
Gowda, Nagesh S.
Aithal, Kiran
Samiulla, D. S.
Mukherjee, Subhendu
Chelur, Shekar
Nellore, Kavitha
Daginakatte, Girish
Ramachandra, Murali
Samajdar, Susanta
CANCER RESEARCH, 2019, 79 (13)
[10] Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models
Stefka, Andrew
Johnson, David
Rosebeck, Shaun
Park, Jae-Hyun
Nakamura, Yusuke
Jakubowiak, Andrzej J.
BLOOD, 2017, 130

← 1 2 3 4 5 →